Figure 6. Validation of risk scores in different immunotherapy cohorts. (A) Kaplan-Meier analysis of different risk scores and response to drugs in the GSE78220 cohort. (B) Kaplan-Meier analysis of different risk scores and response to drugs in the IMvigor-210 cohort. (C, D) Frequency of somatic mutations in different risk score groups.